As per MRFR analysis, the India Sacroiliitis Market Size was estimated at 12.23 (USD Million) in 2023. The India Sacroiliitis Market Industry is expected to grow from 14.56(USD Million) in 2024 to 73 (USD Million) by 2035. The India Sacroiliitis Market CAGR (growth rate) is expected to be around 15.781% during the forecast period (2025 - 2035).
Key India Sacroiliitis Market Trends Highlighted
The India Sacroiliitis Market has seen notable trends in recent times, particularly due to the increasing prevalence of inflammatory conditions and lifestyle changes affecting the population. With a rising number of individuals experiencing symptoms related to sacroiliitis, there is a growing awareness about the condition and its management. This trend is partly fueled by the digital health movement in India, where patients are seeking information online about their symptoms and treatment options.Â
Additionally, the healthcare sector in India is focusing more on research and development for effective therapies targeting sacroiliitis, which reflects another crucial market trend.Key market drivers include a surge in healthcare expenditure and improvements in medical infrastructure across urban and rural areas. The Indian government is investing in healthcare policies aimed at improving access to diagnostic and treatment facilities for musculoskeletal disorders. As a result, hospitals and clinics are increasingly equipped with advanced imaging technologies, enabling early diagnosis and treatment of conditions like sacroiliitis.Â
Moreover, the introduction of new biological therapies tailored for autoimmune diseases is gaining popularity, which can provide relief for patients suffering from chronic pain associated with sacroiliitis.Opportunities to be explored in this market include the expansion of telemedicine services, which can bridge the gap for patients in remote areas who struggle to access specialist care. The increasing focus on preventive healthcare and wellness programs offers avenues for patient education regarding sacroiliitis management and lifestyle modification.Â
Overall, the India Sacroiliitis Market is evolving, driven by the interplay of awareness, technological advancements, and healthcare policy reforms that encourage effective treatment pathways for affected individuals.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
India Sacroiliitis Market Drivers
Rising Prevalence of Autoimmune Disorders
The rising prevalence of autoimmune illnesses in India is majorly driving the growth of the India Sacroiliitis Market. According to reports, autoimmune disorders are on the rise, with the Indian Council of Medical Research estimating that around 30 million people in India suffer from them. This spike increases the likelihood of illnesses such as sacroiliitis, driving the need for appropriate treatments and therapies.
 Organizations such as the All India Institute of Medical Sciences (AIIMS) have spoken out about the need for comprehensive autoimmune illness care, paving the path for a better understanding and improving treatment techniques in sacroiliitis. This steady increase highlights the market's future potential, particularly as diagnostic facilities improve and knowledge of chronic disorders grows among the Indian populace.
the Advancements in Diagnostic Techniques
Advancements in diagnostic technologies and methodologies within India are enhancing the diagnosis and subsequent treatment of sacroiliitis. The availability of magnetic resonance imaging (MRI) and computed tomography (CT) scans has made it possible to effectively identify sacroiliitis cases.Â
According to recent findings published by the Indian Radiological Society, the accuracy of MRI in diagnosing sacroiliitis has improved by nearly 70% compared to traditional methods.As healthcare infrastructure in India continues to improve, an increasing number of healthcare facilities are incorporating these technologies, thus expanding access to early diagnosis and treatment, which will positively impact the India Sacroiliitis Market Industry.
Increase in Geriatric Population
India is witnessing a significant rise in its geriatric population, which is a key driver for the India Sacroiliitis Market Industry. The World Population Prospects estimates that the percentage of the population aged 60 and above is projected to rise from 8% in 2021 to 19% by 2050. Older individuals are more susceptible to degenerative conditions, including sacroiliitis, which necessitates increased healthcare services and interventions.Â
This demographic shift presents a considerable opportunity for market players to develop specialized treatments catering to this age group.Furthermore, organizations like the Ministry of Health and Family Welfare in India are recognizing the need for enhanced healthcare services for the elderly, indicating a proactive approach to addressing age-related health issues, which further empowers market growth.
Growing Awareness and Educational Initiatives
Public awareness and educational initiatives concerning sacroiliitis and related disorders are becoming more prevalent in India. Campaigns led by health organizations, such as the Indian Rheumatology Association, are focused on educating healthcare professionals and the general populace about the signs and symptoms of sacroiliitis.Â
A national survey indicated that awareness of inflammatory arthritis-related conditions has increased by over 40% in urban regions over the last five years.The rise in patient education is expected to lead to earlier diagnoses and treatment initiation, creating a strong demand for therapeutic solutions in the India Sacroiliitis Market Industry. As a result, a well-informed population is likely to pursue healthcare options more actively, thereby fueling market growth.
Sacroiliitis Market Diagnosis Insights
The Diagnosis segment of the India Sacroiliitis Market plays a crucial role in the overall management and treatment of the condition. A variety of diagnostic tools are essential for the accurate identification of sacroiliitis, allowing for timely intervention that can significantly improve patient outcomes. Imaging tests are particularly significant, as they provide detailed visualizations of the sacroiliac joints, which can reveal inflammation and structural abnormalities and assist in differentiating sacroiliitis from other conditions that cause lower back pain.The use of advanced imaging modalities such as MRI and CT scans is steadily increasing in India due to advancements in technology and the growing awareness of the importance of accurate diagnoses ineffective treatment plans.Â
Furthermore, anesthetic injections serve a dual purpose; not only can they aid in therapeutic relief, but they also play a diagnostic role by confirming whether pain relief from the injection correlates with sacroiliac joint dysfunction. This duality enhances their significance in clinical settings as they provide both immediate relief and valuable information regarding the source of the pain.The rising prevalence of conditions leading to sacroiliitis, along with an increase in awareness and access to healthcare services across India, is driving the demand for effective diagnostic procedures.Â
Moreover, initiatives by the Indian government and health organizations to improve diagnostic facilities and reduce the burden of musculoskeletal disorders are fostering growth within this segment. As more healthcare providers incorporate comprehensive diagnostic protocols into their practices, the overall efficacy of treatment for sacroiliitis is expected to improve, reinforcing the importance of this segment in the market landscape.The focus on early and accurate diagnosis represents a significant trend, underscoring the necessity of continual investment in innovative diagnostic solutions within the India Sacroiliitis Market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Sacroiliitis Market Treatment Insights
The Treatment segment of the India Sacroiliitis Market presents a robust landscape for addressing the condition, with several key approaches that reflect the evolving needs of patients. Medications, which comprise anti-inflammatory drugs and analgesics, play a central role in easing symptoms and improving the quality of life for patients. Joint Injections offer targeted relief, allowing for the delivery of potent anti-inflammatory substances directly to the affected area, thus significantly reducing pain and inflammation. Joint Fusion serves as a more invasive treatment option for chronic cases, providing stability to the affected joints and helping restore functional mobility.
Meanwhile, Radiofrequency Denervation has emerged as a minimally invasive procedure that interrupts nerve signals contributing to pain, offering long-term relief for many patients. The growth of these treatment options is driven by increasing awareness of sacroiliitis and advancements in medical technologies. The rising prevalence of inflammatory diseases and lifestyle factors in India further accentuate the demand for effective treatment modalities. As the population ages, there is an evident opportunity for innovative therapies that can cater to diverse patient needs.Overall, the Treatment segment is pivotal in enhancing patient outcomes and holds significant promise for future growth within the India Sacroiliitis Market.
Sacroiliitis Market End User Insights
The End User segment of the India Sacroiliitis Market is crucial for understanding the pathways through which patients receive diagnosis and treatment. Hospitals play a pivotal role as they often serve as the frontline for patient care. They provide comprehensive services, including diagnostic imaging, pain management, and surgical interventions, which are essential for individuals suffering from sacroiliitis. The accessibility and advancements in hospital care greatly influence patient outcomes, thereby driving the market growth in India.Â
Diagnostic Centers also convey significant importance by providing specialized tests and imaging services, which are crucial for the accurate diagnosis and ongoing management of sacroiliitis. As awareness about sacroiliitis increases, the demand for quality diagnostic services is expected to rise accordingly. Furthermore, the integration of technology in these facilities enhances the efficiency and effectiveness of patient care, contributing to the overall growth of the market. As such, both Hospitals and Diagnostic Centers represent vital components in the landscape of the India Sacroiliitis Market and influence various aspects of patient treatment pathways, contributing to trends in market growth statistics and segmentation dynamics.
India Sacroiliitis Market Key Players and Competitive Insights
The India Sacroiliitis Market is characterized by a growing awareness of treatment options and the increasing prevalence of autoimmune and inflammatory diseases. As healthcare progresses, the market for sacroiliitis advancements exhibits a dynamic competitive landscape marked by both established pharmaceutical companies and emerging players. These companies are actively engaged in research and development to enhance therapeutic outcomes for patients suffering from sacroiliitis. The market's competitiveness is further driven by innovations in drug formulations and the strategic alignment of marketing efforts with patient needs. With an emphasis on patient-centric approaches, multiple players are vying to capture market share, thereby fostering an environment of continuous growth and clinical exploration.
BristolMyers Squibb has established a significant presence within the India Sacroiliitis Market through its robust portfolio of immune-oncology therapies. The company's strengths lie in its expertise in molecular targets and biologics, which provide innovative treatment options for sacroiliitis and related inflammatory conditions. Their continuous investment in local clinical trials and collaborations with Indian healthcare institutions reinforce their commitment to understanding regional patient demographics better. BristolMyers Squibb's strategic focus on ensuring drug accessibility through competitive pricing and patient assistance programs has contributed to its solid position in the Indian market, making its therapies the preferred choice among healthcare professionals managing sacroiliitis.Sanofi India has made notable strides in the India Sacroiliitis Market characterized by its comprehensive range of treatment options tailored to autoimmune disorders. The company's prominent offerings include disease-modifying antirheumatic drugs that cater to patients diagnosed with sacroiliitis.Â
Sanofi India's strength lies in its extensive distribution network and collaboration with local healthcare providers, which aids in reaching a wider patient base. The company has also been involved in partnerships that enhance its market presence, strengthening its ability to innovate based on local needs. Additionally, any recent mergers and acquisitions have only served to bolster its portfolio in the segment, positioning Sanofi as a significant player in the therapeutic domain. Through targeted marketing strategies and community outreach initiatives, Sanofi India continues to enhance its visibility in the sacroiliitis market, thereby reinforcing its stature in the competitive landscape of India.
Key Companies in the India Sacroiliitis Market Include:
India Sacroiliitis Market Industry Developments
The India Sacroiliitis Market has experienced significant developments recently. Companies like BristolMyers Squibb and Novartis India are focusing on expanding their portfolios with innovative treatments aimed at alleviating inflammation associated with sacroiliitis. In September 2023, AstraZeneca Pharma India announced a collaboration with local research institutions to advance treatments and improve patient outcomes.Â
The market has seen increased investments driven by the growing prevalence of autoimmune conditions, with an emphasis on Biologics and specialty pharmaceuticals. In April 2022, Sun Pharmaceutical Industries expanded its research initiatives aimed at developing targeted therapies for inflammatory conditions, including sacroiliitis, which is anticipated to enhance its market position. Regarding mergers and acquisitions, there have been no significant transactions involving the companies of interest within the last two years.Â
Nevertheless, the market valuation for firms active in treatments for sacroiliitis is on the rise due to an uptick in patient awareness and diagnosis. Major healthcare organizations in India have reported a growing incidence of sacroiliitis, creating a favorable environment for pharmaceutical growth and collaboration in this therapeutic category. The ongoing advancements in treatment modalities and patient management underscore the dynamic nature of this market segment.
India Sacroiliitis Market Segmentation Insights
Sacroiliitis Market Diagnosis Outlook
Sacroiliitis Market Treatment Outlook
Sacroiliitis Market End User Outlook
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 12.23(USD Million) |
| MARKET SIZE 2024 | 14.56(USD Million) |
| MARKET SIZE 2035 | 73.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 15.781% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | BristolMyers Squibb, Sanofi India, AstraZeneca Pharma India, Zydus Cadila, Dr. Reddy's Laboratories, Novartis India, Cipla, GlaxoSmithKline Pharmaceuticals, Mylan Laboratories, Pfizer India, Abbott India, Lupin Pharmaceuticals, Merck Ltd, Boehringer Ingelheim India, Sun Pharmaceutical Industries |
| SEGMENTS COVERED | Diagnosis, Treatment, End User |
| KEY MARKET OPPORTUNITIES | Growing prevalence of autoimmune disorders, Rising demand for biologic therapies, Increasing awareness among healthcare providers, Expansion of telehealth services, Advancements in diagnostic imaging technology |
| KEY MARKET DYNAMICS | increasing prevalence of autoimmune diseases, growing geriatric population, advancements in diagnostic techniques, rise in healthcare expenditure, awareness about chronic pain management |
| COUNTRIES COVERED | India |
Frequently Asked Questions (FAQ) :
The expected market size of the India Sacroiliitis Market in 2024 is valued at 14.56 million USD.
By the year 2035, the market size for the India Sacroiliitis Market is projected to reach 73.0 million USD.
The CAGR for the India Sacroiliitis Market from 2025 to 2035 is expected to be 15.781%.
In 2024, the Imaging Tests segment is expected to hold a larger market share valued at 8.0 million USD compared to Anesthetic Injections at 6.56 million USD.
The anticipated market value for Imaging Tests in the India Sacroiliitis Market by 2035 is 40.0 million USD.
The market size for Anesthetic Injections in the India Sacroiliitis Market is projected to reach 33.0 million USD by 2035.
Key players in the India Sacroiliitis Market include Bristol-Myers Squibb, Sanofi India, and AstraZeneca Pharma India among others.
Significant opportunities for growth in the India Sacroiliitis Market arise from advancements in diagnostic technologies and increasing awareness of sacroiliitis.
The India Sacroiliitis Market is projected to experience substantial growth from 2025 to 2035 driven by rising incidence rates and improved diagnostic methods.
Challenges such as high costs of advanced imaging technologies may affect the growth of the India Sacroiliitis Market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
